Subscribe To

Price Alert Latest News Economic Calendar News

RIGL / Rigel Pharmaceuticals: Why The Stock Is On A Run

RIGL announced Q4'21 earnings in early March leading the stock to rally over 20%. Read More

Demo Live Account See Partner Details

Content Topics

RIGL

Posted: Mar 21 2022, 17:35

Author Name: Seeking Alpha

RIGL News

By PRNewsWire
August 30, 2023

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the compa

By Seeking Alpha
August 1, 2023

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Co

By Zacks Investment Research
August 1, 2023

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares t

By Zacks Investment Research
May 2, 2023

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares t

By Seeking Alpha
April 27, 2023

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability.

By PRNewsWire
April 25, 2023

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first

By Seeking Alpha
March 7, 2023

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Cou

By Zacks Investment Research
March 7, 2023

Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold cl

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.